McKesson to Separate Medical-Surgical Unit; Apollo Invests $1.25B
McKesson Corporation announced a new four-segment reporting structure in fiscal 2026, comprising North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company intends to separate its Medical-Surgical Solutions segment into an independent company, with Apollo Funds acquiring a 13% minority ownership interest for approximately $1.25 billion. Additionally, McKesson completed the sale of its Norwegian operations during fiscal 2026, reflecting strategic initiatives to focus on core healthcare businesses.
Key Highlights
- Implemented new four-segment reporting structure in fiscal 2026.
- Intends to separate Medical-Surgical Solutions segment into an independent company.
- Apollo Funds to acquire 13% minority stake in Medical-Surgical Solutions for $1.25 billion.
- Completed sale of Norwegian operations during fiscal 2026.
- North American Pharmaceutical segment distributes drugs in U.S. and Canada.
- Oncology & Multispecialty segment includes specialty drug distribution and U.S. Oncology Network.
- Prescription Technology Solutions addresses medication access and affordability.
- Medical-Surgical Solutions provides supplies to non-acute settings in the U.S.
Price Impact
More from MCK
McKesson Q1 EPS $5.15; Sells 13% Medical-Surgical Stake for $1.25B
McKesson Q1 Adj. EPS $9.93 (+20%); Raises FY27 Guidance to $44.20-$45.00
McKesson Announces Executive Vice President Retirement, New Appointment